GLIPIZIDE

Glipizide Adverse Events Reported to the FDA Over Time

How are Glipizide adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Glipizide, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Glipizide is flagged as the suspect drug causing the adverse event.

Most Common Glipizide Adverse Events Reported to the FDA

What are the most common Glipizide adverse events reported to the FDA?

Blood Glucose Increased	395 (6.4%)
Hypoglycaemia	332 (5.38%)
Blood Glucose Decreased	169 (2.74%)
Completed Suicide	168 (2.72%)
Drug Ineffective	147 (2.38%)
Dizziness	107 (1.73%)
Nausea	94 (1.52%)
Diabetes Mellitus Inadequate Contro...	92 (1.49%)
Diarrhoea	71 (1.15%)
Malaise	68 (1.1%)
Asthenia	66 (1.07%)
	Show More
Blood Glucose Fluctuation	63 (1.02%)
Death	63 (1.02%)
Drug Interaction	62 (1%)
Vomiting	60 (.97%)
Weight Increased	57 (.92%)
Hyperhidrosis	55 (.89%)
Tremor	54 (.87%)
Fatigue	50 (.81%)
Loss Of Consciousness	50 (.81%)
Abdominal Pain Upper	49 (.79%)
Convulsion	48 (.78%)
Glycosylated Haemoglobin Increased	43 (.7%)
Feeling Abnormal	40 (.65%)
Fall	39 (.63%)
Weight Decreased	39 (.63%)
Confusional State	37 (.6%)
Decreased Appetite	37 (.6%)
Dyspnoea	37 (.6%)
Chest Pain	34 (.55%)
Headache	33 (.53%)
Hypersensitivity	32 (.52%)
Drug Toxicity	31 (.5%)
Syncope	31 (.5%)
Blood Glucose Abnormal	30 (.49%)
Cardiac Disorder	30 (.49%)
Vision Blurred	30 (.49%)
Hypertension	29 (.47%)
Medication Error	29 (.47%)
Muscle Spasms	27 (.44%)
Oedema Peripheral	27 (.44%)
Rash	27 (.44%)
Anaemia	26 (.42%)
Poisoning	26 (.42%)
Renal Failure Acute	26 (.42%)
Medication Residue	25 (.4%)
Pain In Extremity	25 (.4%)
Mental Status Changes	24 (.39%)
Drug Effect Decreased	23 (.37%)
Hyperglycaemia	23 (.37%)
Hyperkalaemia	23 (.37%)
Visual Impairment	23 (.37%)
Nervousness	22 (.36%)
Respiratory Arrest	22 (.36%)
Abdominal Distension	21 (.34%)
Abdominal Pain	21 (.34%)
Cardiac Arrest	21 (.34%)
Depressed Level Of Consciousness	21 (.34%)
Hunger	21 (.34%)
Insomnia	21 (.34%)
Myocardial Infarction	21 (.34%)
Pneumonia	21 (.34%)
Somnolence	21 (.34%)
Pruritus	20 (.32%)
Anorexia	19 (.31%)
Weight Fluctuation	19 (.31%)
Abdominal Discomfort	18 (.29%)
Burning Sensation	18 (.29%)
Intentional Drug Misuse	18 (.29%)
Treatment Noncompliance	18 (.29%)
Depression	17 (.28%)
Multiple Drug Overdose	17 (.28%)
Presyncope	17 (.28%)
Blood Creatinine Increased	16 (.26%)
Drug Hypersensitivity	16 (.26%)
Lethargy	16 (.26%)
Myalgia	16 (.26%)
Pulse Abnormal	16 (.26%)
Blood Pressure Increased	15 (.24%)
Condition Aggravated	15 (.24%)
Gastrointestinal Disorder	15 (.24%)
Incorrect Dose Administered	15 (.24%)
Lactic Acidosis	15 (.24%)
Lung Disorder	15 (.24%)
Palpitations	15 (.24%)
Product Substitution Issue	15 (.24%)
Drug Dispensing Error	14 (.23%)
Feelings Of Worthlessness	14 (.23%)
Metabolic Acidosis	14 (.23%)
Overdose	14 (.23%)
Pain	14 (.23%)
Rash Pruritic	14 (.23%)
Renal Disorder	14 (.23%)
Therapeutic Response Unexpected	14 (.23%)
Therapeutic Response Unexpected Wit...	14 (.23%)
Alanine Aminotransferase Increased	13 (.21%)
Anxiety	13 (.21%)
Diabetes Mellitus	13 (.21%)
Heart Rate Increased	13 (.21%)
Hypophagia	13 (.21%)
Product Quality Issue	13 (.21%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Glipizide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Glipizide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Glipizide

What are the most common Glipizide adverse events reported to the FDA?

Metabolic, Nutritional And Blood Ga...	711 (11.52%)
Glucose Metabolism Disorders	478 (7.74%)
Neurological	393 (6.37%)
Gastrointestinal Signs	303 (4.91%)
Therapeutic And Nontherapeutic Effe...	296 (4.8%)
Suicidal And Self-injurious Behavio...	173 (2.8%)
Medication Errors	172 (2.79%)
Epidermal And Dermal Conditions	129 (2.09%)
Respiratory	116 (1.88%)
Physical Examination Topics	115 (1.86%)
Appetite And General Nutritional	104 (1.68%)
	Show More
Infections - Pathogen Unspecified	95 (1.54%)
Gastrointestinal Motility And Defec...	89 (1.44%)
Skin Appendage Conditions	75 (1.21%)
Cardiac And Vascular Investigations	74 (1.2%)
Chemical Injury And Poisoning	73 (1.18%)
Injuries	72 (1.17%)
Vision	71 (1.15%)
Renal Disorders	69 (1.12%)
Muscle	65 (1.05%)
Anxiety Disorders	64 (1.04%)
Fatal Outcomes	64 (1.04%)
Product Quality Issues	60 (.97%)
Allergic Conditions	58 (.94%)
Cardiac Arrhythmias	58 (.94%)
Movement Disorders	58 (.94%)
Electrolyte And Fluid Balance Condi...	57 (.92%)
Hepatic And Hepatobiliary	52 (.84%)
Seizures	52 (.84%)
Anemias Nonhemolytic And Marrow Dep...	50 (.81%)
Psychiatric	48 (.78%)
Deliria	47 (.76%)
Cardiac Disorder Signs	46 (.75%)
Musculoskeletal And Connective Tiss...	41 (.66%)
Coronary Artery	39 (.63%)
Headaches	38 (.62%)
Lifestyle Issues	38 (.62%)
Renal And Urinary Tract Investigati...	38 (.62%)
Hematology Investigations	37 (.6%)
Urinary Tract Signs	34 (.55%)
Acid-base	32 (.52%)
Depressed Mood Disorders	32 (.52%)
Hepatobiliary	32 (.52%)
Oral Soft Tissue Conditions	32 (.52%)
Vascular Hypertensive	31 (.5%)
Administration Site Reactions	29 (.47%)
Joint	26 (.42%)
Water, Electrolyte And Mineral	24 (.39%)
Bone And Joint Injuries	23 (.37%)
Central Nervous System Vascular	22 (.36%)
Lower Respiratory Tract Disorders	22 (.36%)
Gastrointestinal Conditions	21 (.34%)
Peripheral Neuropathies	21 (.34%)
Sleep Disorders	21 (.34%)
Gastrointestinal Ulceration And Per...	20 (.32%)
Decreased And Nonspecific Blood Pre...	18 (.29%)
Mood Disorders	18 (.29%)
Arteriosclerosis, Stenosis, Vascula...	16 (.26%)
Bacterial Infectious	16 (.26%)
Procedural And Device Related Injur...	16 (.26%)
Tongue Conditions	16 (.26%)
Exocrine Pancreas Conditions	15 (.24%)
Eye	15 (.24%)
Gastrointestinal Hemorrhages	15 (.24%)
Heart Failures	15 (.24%)
Therapeutic Procedures And Supporti...	15 (.24%)
Viral Infectious	15 (.24%)
Lipid Analyses	14 (.23%)
Gallbladder	13 (.21%)
Inner Ear And Viiith Cranial Nerve	12 (.19%)
Skin Vascular Abnormalities	12 (.19%)
Anal And Rectal Conditions	11 (.18%)
Bronchial Disorders	11 (.18%)
Gastrointestinal Inflammatory Condi...	11 (.18%)
Mental Impairment	11 (.18%)
Ocular Sensory Symptoms	11 (.18%)
Upper Respiratory Tract Disorders	11 (.18%)
Body Temperature Conditions	10 (.16%)
Psychiatric And Behavioural Symptom...	10 (.16%)
Reproductive Neoplasms Male Maligna...	10 (.16%)
Tissue	10 (.16%)
Angiedema And Urticaria	9 (.15%)
Bone Disorders	9 (.15%)
Ocular Neuromuscular	9 (.15%)
Sexual Function And Fertility	9 (.15%)
Skin And Subcutaneous Tissue	9 (.15%)
Gastrointestinal Neoplasms Malignan...	8 (.13%)
Salivary Gland Conditions	8 (.13%)
Toxicology And Therapeutic Drug Mon...	8 (.13%)
Vascular	8 (.13%)
Disturbances In Thinking	7 (.11%)
Enzyme	7 (.11%)
Glaucoma And Ocular Hypertension	7 (.11%)
Schizophrenia And Other Psychotic	7 (.11%)
Sleep Disturbances	7 (.11%)
Dental And Gingival Conditions	6 (.1%)
Embolism And Thrombosis	6 (.1%)
Hematological And Lymphoid Tissue T...	6 (.1%)
Injuries By Physical Agents	6 (.1%)
Investigations, Imaging And Histopa...	6 (.1%)
Lipid Metabolism	6 (.1%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Glipizide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Glipizide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.